

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 020 469 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication: 19.07.2000 Bulletin 2000/29 (51) Int Cl.7: **C07D 491/06, A61K 31/55**  
// (C07D491/06, 307:00, 223:00)

(21) Application number: 00107569.6

(22) Date of filing: 10.10.1994

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE**

(30) Priority: 15.10.1993 US 137443

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  
**94115960.0 / 0 648 771**

(71) Applicant: **SYNAPTECH, INC.**  
**Cold Spring Harbor, NY 11724 (US)**

(72) Inventors:  
• **Kosley, JR., Raymond W.**  
**Bridgewater NJ 08807 (US)**

• **Taberna, Veronica**  
**Union NJ 07083 (US)**  
• **Davis, Larry**  
**Sergeantsville NJ 08557 (US)**


(74) Representative:  
**Ebner von Eschenbach, Jennifer**  
**c/o Ladas & Parry,**  
**Dachauerstrasse 37**  
**80335 München (DE)**

Remarks:

This application was filed on 07 - 04 - 2000 as a divisional application to the application mentioned under INID code 62.

(54) **Galanthamine derivatives, a process for their preparation and their use as medicaments**

(57) A compound of the formula (II)



(II)

wherein

R<sup>1</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl, mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl, or di(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl;

R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy, di(C<sub>1</sub>-C<sub>8</sub>)alkylaminocarbonyloxy, or aryl(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyloxy;

R<sup>3</sup> is hydrogen, halo or (C<sub>1</sub>-C<sub>4</sub>)alkyl; or a pharmaceutically acceptable acid addition salt thereof.

EP 1 020 469 A2

## Description

[0001] This application relates to compounds of the formula



15 wherein

R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl, mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl or di(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl;

R<sup>2</sup> is (C<sub>1</sub>-C<sub>11</sub>)monoalkylaminocarbonyloxy, (C<sub>1</sub>-C<sub>12</sub>)dialkylaminocarbonyloxy or aryl(C<sub>1</sub>-C<sub>4</sub>)-alkylaminocarbonyloxy);

20 R<sup>3</sup> is hydrogen, halo or (C<sub>1</sub>-C<sub>4</sub>)alkyl; or a pharmaceutically acceptable addition salt thereof;

which are useful for inhibiting acetylcholinesterase and alleviating various memory dysfunctions characterized by decreased cholinergic function such as Alzheimer's disease.

[0002] This invention also provides a pharmaceutical composition useful for inhibiting acetylcholinesterase and alleviating various memory dysfunctions characterized by decreased cholinergic function which comprises a compound of the invention in an amount sufficient to affect cholinergic function and a pharmaceutically acceptable carrier.


[0003] Unless otherwise stated or indicated, the following definitions shall apply throughout the specification and appended claims.

[0004] The term "alkyl" shall mean a straight or branched alkyl group of the stated number of carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and pentadecyl.

[0005] The term "halo" shall mean chloro, fluoro, bromo and iodo.

[0006] The term "aryl" shall mean phenyl having 0, 1, 2 or 3 substituents independently selected from the group of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl, halo or trifluoromethyl.

[0007] In one embodiment of the invention are compounds of the formula (II)



wherein

R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl, mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl, or di(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl;

R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>18</sub>)alkylaminocarbonyloxy, di(C<sub>1</sub>-C<sub>8</sub>)alkylaminocarbonyloxy, or aryl(C<sub>1</sub>-C<sub>4</sub>)-alkylaminocarbonyloxy;

R<sup>3</sup> is hydrogen or halo; and pharmaceutically acceptable addition salts.


[0008] In a preferred embodiment are compounds of Formula II wherein R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>12</sub>)-alkylaminocarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl or (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl; R<sup>2</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy or phenyl(C<sub>1</sub>-C<sub>3</sub>)alkylaminocarbonyloxy; and R<sup>3</sup> is hydrogen or halogen.

[0009] More preferably R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl or (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl; R<sup>2</sup> is (C<sub>1</sub>-C<sub>10</sub>)-alkylaminocarbonyloxy or phenyl(C<sub>1</sub>-C<sub>2</sub>)alkylaminocarbonyloxy; and R<sup>3</sup> is hydrogen.

[0010] Most preferably  $R^1$  is hydrogen, methylcarbonyl, ethylcarbonyl, isopropylcarbonyl, t-butylcarbonyl, n-heptylcarbonyl or t-butoxycarbonyl;  $R^2$  is methylaminocarbonyloxy, isopropylaminocarbonyloxy, t-butylaminocarbonyloxy, n-pentylaminocarbonyloxy, n-hexylaminocarbonyloxy, n-heptylaminocarbonyloxy, n-octylaminocarbonyloxy or n-nonylaminocarbonyloxy; and  $R^3$  is hydrogen.

[0011] The compounds of the invention are prepared from the appropriate derivative of galanthamine as described more fully below and shown in Scheme I.

SCHEME I



[0012] The intermediate 6-demethylgalanthamine of Formula IV, a known compound, was prepared in a novel process by treating the galanthamine of Formula III with an alkaline salt of ethanthiol such as, for example, with EtSLi, EtSNa or EtSK. The reaction is typically carried out in a polar nonprotic solvent such as dimethylformamide (DMF) or N-methylpyrrolidone or a protic solvent such as butanol or pentanol at from about 80 ° C to about 135 ° C, preferably from about 90 ° C to about 125 ° C.

[0013] The compound of Formula V wherein  $R^4$  is hydrogen and  $R^5$  is  $(C_1-C_{12})$ alkyl, or phenyl $(C_1-C_6)$ alkyl is prepared by treating the compound of Formula IV with the appropriate isocyanato compound  $R^5-NCO$ . The reaction is carried out in an aprotic solvent such as, for example, tetrahydrofuran in the presence of base such as, for example, potassium carbonate at from about -10°C to about 30°C for from about 0.5 hours to about 4 hours.

[0014] Alternatively and in the case where  $R^4$  and  $R^5$  are not hydrogen, the compound of Formula V is prepared by first reacting the compound of Formula IV with carbonyldiimidazole and subsequently adding the appropriate  $R^4R^5-NH$  compound. The reaction is typically carried out in a nonprotic organic solvent such as methylene chloride, chloroform or tetrahydrofuran (THF) at from about -10°C to about 50°C, preferably from about 0 ° C to about 30 ° C.

[0015] The compound of Formula VI can be prepared from the compound of Formula V. In the case where  $R^6$  is alkylamino or arylamino, a solution of the appropriate isocyanate and the compound V in a nonprotic solvent such as tetrahydrofuran in a sealed tube at from about 55 ° C to about 85 ° C for from about 24 hours to about 120 hours, preferably from about 60 ° C to about 70 ° C for from about 60 hours to about 80 hours. Alternatively, where  $NR^4R^5$  and  $R^6$  are identical, the compounds are made from the compound of Formula IV using over two moles of the appropriate isocyanate in a sealed tube as described above.

[0016] In the case where  $R^6$  is alkyl or aryl, the compound of Formula V is typically reacted with an appropriate carboxylic anhydride in the presence of a base such as 4-dimethylaminopyridine (DMAP) or pyrrolidinopyridine or carboxylic acid chloride in the presence of a base such as 1,8-diaza-bicyclo[5.4.0]-undec-7-ene (DBU). The reactions are typically carried out in a non-protic solvent such as, for example, chloroform or dichloromethane at from about 0°C to about 50 ° C, preferably at from about 15 ° C to about 30 ° C.

[0017] In the case where  $R^6$  is alkoxy or aryloxy, the compound of Formula V is typically reacted with the appropriate chloroformate in the presence of an amine such as triethylamine; or with the appropriate dicarbonate in the presence of an amine such as DMAP. The reactions are typically carried out in an inert organic solvent such as methylene chloride at from about -10 ° C to about 50 ° C, preferably from about 0 ° C to about 30 ° C.

[0018] In the case where X is Br, the compound of Formula IV is treated with bromine in the presence of an amine such as t-butylamine to obtain the brominated compound. The bromine is first added to the t-butylamine at from about -20 ° C to about -30 ° C, then the reaction mixture is cooled to about -80 ° C to about -70 ° C and the galanthamine compound is added. The reaction is typically carried out in a nonpolar organic solvent such as for example toluene. Following addition of galanthamine the mixture is allowed to warm from about -70°C to -80°C to about room temperature for from about 6 hours to about 10 hours, preferably about 8 hours.

[0019] The compounds of Formula I of the present invention can be used for the treatment of various memory dysfunctions characterized by decreased cholinergic function, such as Alzheimer's disease. The compounds to of the present invention are advantageous because they are less toxic and/or more potent than the related compounds known in the art.

[0020] This utility is manifested by the ability of these compounds to inhibit the enzyme acetylcholinesterase and thereby increase acetylcholine levels in the brain.

[0021] The ability to inhibit acetylcholinesterase was determined by the photometric method of Ellman et al., Biochem. Pharmacol 7.88 (1961). Results of acetylcholinesterase inhibition for some of the compounds of this invention are presented in Table I along with those for reference compounds.

TABLE I

Acetylcholinesterase Inhibition Assay	
Compound	IC <sub>50</sub> μM CHE I
6-O-Demethyl-6-O-(methylaminocarbonyl)galanthamine	0.0020
6-O-Demethyl-6-O-methylaminocarbonyl-3-O-(2-propylcarbonyl)galanthamine hydrochloride	0.047
Tacrine	0.32

[0022] This utility can also be ascertained by determining the ability of these compounds to restore cholinergically deficient memory in the Dark Avoidance Assay. In this assay mice are tested for their ability to remember an unpleasant stimulus for a period of 24 hours. A mouse is placed in a chamber that contains a dark compartment; a strong incandescent light drives it to the dark compartment, where an electric shock is administered through metal plates on the floor. The animal is removed from the testing apparatus and tested again, 24 hours later, for the ability to remember the electric shock.

[0023] If scopolamine, an anticholinergic that is known to cause memory impairment, is administered before an animal's initial exposure to the test chamber, the animal re-enters the dark compartment shortly after being placed in the test chamber 24 hours later. This effect of scopolamine is blocked by an active test compounds, resulting in a greater Interval before re-entry into the dark compartment.

[0024] The test results are expressed as the percent of a group of animals in which the effect of scopolamine is blocked, as manifested by an increased interval between being placed in the test chamber and reentering the dark compartment. Results of Dark Avoidance Assay for some of the compounds of this invention are presented in Table II along with a result for a reference compounds.

TABLE II

Compound	SDDA Dose (mg/kg, s.c.)	Percent of Animals with Scopolamine Induced Memory Deficit Reversal
6-O-Demethyl-6-O-(methylaminocarbonyl)galanthamine	0.003	27
Tacrine	0.31	33

[0025] Effective quantities of the compounds of the invention may be administered to a patient by any of the various methods, for example, orally as in capsule or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.

[0026] Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids.

[0027] The active compounds of the present invention may be orally administered, for example, with an inert diluent

or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compounds, but may be varied depending upon the particular form and may conveniently be between 5% to about 70% of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0 - 200 milligrams of active compound.

**[0028]** The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as micro-crystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above-type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

**[0029]** For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied between 0.5 and about 30% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present inventions are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.

**[0030]** The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral multiple dose vials may be of glass or plastic.

**[0031]** The following Table III and examples will further illustrate this invention but are not intended to limit it in any way. In Table III typical compounds of the instant invention are listed. Following Table III, representative illustrative preparations of compounds of the invention are described.




TABLE III				
				
EX. No.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	m.p. °C
1	H	OH	H	225-229°
2	H	OC(=O)NHCH <sub>3</sub>	H	196-197
3	H	OC(=O)NH(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	H	222-224°

TABLE III



EX. No.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	m.p. °C
4	H	OC(=O)NH(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	H	217-218d
5	H	OC(=O)NH(CH <sub>2</sub> ) <sub>5</sub> CH <sub>3</sub>	H	220-222 <sup>a</sup>
6	Cl(=O)CH <sub>3</sub>	OC(=O)NHCH <sub>3</sub>	H	178d <sup>a</sup>
7	H	OC(=O)NH(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	H	210-212 <sup>a</sup>
8	Cl(=O)NH(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	OC(=O)NH(CH <sub>2</sub> ) <sub>6</sub> CH <sub>3</sub>	H	215-217 <sup>a</sup>
9	H	OC(=O)NHC(CH <sub>3</sub> ) <sub>3</sub>	H	230-232 <sup>a</sup>
10	H	OC(=O)NHCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	H	210-212 <sup>b</sup>
11	H	OC(=O)NH(CH <sub>2</sub> ) <sub>8</sub> CH <sub>3</sub>	H	205-208 <sup>a</sup>
12	Cl(=O)NH(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	OC(=O)NH(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	H	201-210 <sup>a</sup>
13	Cl(=O)CH(CH <sub>3</sub> ) <sub>2</sub>	OC(=O)NHCH <sub>3</sub>	H	135 <sup>a</sup>
14	Cl(=O)CH(CH <sub>3</sub> ) <sub>2</sub>	OC(=O)NH(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	H	137-140 <sup>a</sup>
15	Cl(=O)C(CH <sub>3</sub> ) <sub>3</sub>	OC(=O)NH(CH <sub>2</sub> ) <sub>7</sub> CH <sub>3</sub>	H	138-140
16	H	OH	Br	138-141

TABLE III



EX. No.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	m.p. <sup>a</sup> °C
17	H	OC(=O)NH(CH <sub>2</sub> ) <sub>14</sub> CH <sub>3</sub>	H	188-191d <sup>a</sup>
18	H	OC(=O)N(CH <sub>3</sub> ) <sub>2</sub>	H	270-272d <sup>a</sup>

<sup>a</sup> Lit. m.p. 220-222<sup>a</sup> isolated as HCl salt

## EXAMPLE 1

## 6-O-Demethylgalanthamine

**[0032]** To a stirred solution of 20 ml of dry DMF at -40° under nitrogen was added 0.57 ml (0.48 g) of ethanethiol. The mixture was stirred for several minutes at -40° to -30° after which 2.84 ml of 2.5 M BuLi in hexanes was added slowly by syringe at -40° to -50°. The solution was then allowed to warm to room temperature over 15 minutes, heated to 50° under aspirator vacuum and again cooled to 30°. To the solution was added a solution of 0.57 g of galanthamine in 5.7 ml of dry DMF. The solution was stirred at 95-100° for 2 hours and subsequently at 100-105° for 3 hours, allowed to cool to room temperature and concentrated to an oil. The oil was dissolved in chloroform, shaken with NH<sub>4</sub>Cl, made basic with aq NaHCO<sub>3</sub> and extracted four times with CHCl<sub>3</sub>. The pH of the aqueous layer was then adjusted to 9-10 with NH<sub>4</sub>OH and again extracted four times with chloroform. The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated to an oil. The oil was dissolved in degassed 5% methanol/chloroform and flash chromatographed on silica gel eluting with the same solvent system followed by 10% methanol/chloroform to provide a beige solid. The material was dissolved in acetone and allowed to crystallize overnight to provide 0.298 g of 6-O-demethylgalanthamine.  
m.p. 225-229°.

## ANALYSIS:

Calculated for C <sub>16</sub> H <sub>9</sub> NO <sub>3</sub>	70.31%C	7.01%H	5.12%N
Found	70.14%C	7.29%H	4.96%N

## EXAMPLE 2

## 6-O-Demethyl-6-O-(methylaminocarbonyl)galanthamine

**[0033]** To a solution of 6-O-demethylgalanthamine (0.5 g) in 30 ml of dry tetrahydrofuran, was added milled K<sub>2</sub>CO<sub>3</sub> (0.3 g) followed by methyl isocyanate (0.1 ml).

**[0034]** After stirring at ambient temperature for twenty hours, the mixture was filtered, and the filtrate evaporated to a tan solid (0.5 g) which was recrystallized from methanol to give 0.3 g (53%) of a solid, m.p. 196-197°C (dec.).

ANALYSIS:			
Calculated for $C_{18}H_{22}N_2O_4$	65.43%C	6.71%H	8.48%N
Found	64.79%C	6.81%H	8.20%N

## EXAMPLE 3

## 6-O-Demethyl-6-O-(n-heptylamino-carbonyl)galanthamine hydrochloride

[0035] To 0.614 g of 6-O-demethylgalanthamine and 0.62 g of milled potassium carbonate was added by syringe 10.5 ml of dry THF. The suspension was cooled in an ice/salt bath after which 0.4 ml of n-heptylisocyanate was added by syringe. The mixture was stirred for 20 minutes at ice bath temperature, allowed to warm to room temperature and stirred at room temperature for 15 minutes. The solution was diluted with dry dichloromethane, cooled in an ice bath to room temperature and poured onto a silica gel column packed with 3% dry methanol/dichloromethane. The column was eluted with this solvent system followed by 5% dry methanol/dichloromethane to provide 0.852 g of an oil. The material was dissolved in ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride, filtered and dried to provide 0.711 g of white crystals. Recrystallization/trituration from isopropyl alcohol provided 0.536 g of 6-O-demethyl-6-O-(n-heptylamino-carbonyl)galanthamine hydrochloride, m.p. 222-224°.

ANALYSIS:			
Calculated for $C_{24}H_{34}N_2O_4 \cdot HCl$	63.92%C	7.82%H	6.21%N
Found	63.86%C	8.19%H	6.06%N

## EXAMPLE 4

## 6-O-Demethyl-6-O-(n-butylamino-carbonyl)galanthamine hydrochloride

[0036] To a stirred suspension of 0.591 g of 6-O-demethylgalanthamine in 10 ml of THF was added 0.6 g of milled potassium carbonate. The suspension was cooled to 0°C and 0.30 ml of n-butyliisocyanate was added by syringe. The suspension was stirred for 1/2 hour at 0° and 45 minutes at room temperature. To the suspension, at room temperature was added an additional 0.30 ml of n-butyliisocyanate after which the suspension was stirred for 1/2 hour at room temperature. The suspension was filtered onto a flash chromatography column packed with silica gel in 3% dry methanol/dichloromethane. Flash chromatography was carried out with 3% dry methanol/dichloromethane followed by 5% dry methanol/dichloromethane to provide an oil which was dissolved in ethyl acetate and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride.

[0037] The material was isolated by filtration and dried to provide 0.611 g of material, m.p. 217-218°Cd.

ANALYSIS:			
Calculated for $C_{21}H_{28}N_2O_4 \cdot HCl$	61.68%C	7.15%H	6.85%N
Found	61.93%C	7.09%H	6.69%N

## EXAMPLE 5

## 6-O-Demethyl-6-O-(n-hexylamino-carbonyl)galanthamine hydrochloride

[0038] To a mixture of 0.80 g of 6-O-demethylgalanthamine and 0.81 g of milled potassium carbonate was added 13.5 ml of THF via a syringe. The suspension was cooled to 0°C and 0.54 ml of n-hexyl isocyanate was added by syringe. The suspension was filtered onto a flash chromatography column packed with silica gel and eluted with 3% dry methanol/dichloromethane followed by 5% dry methanol/dichloromethane. The pure, product-containing fractions were combined and concentrated to provide 0.93 g of a white solid which was dissolved in diethyl ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride to provide 0.82 g of 6-O-demethyl-6-O-(n-hexylamino-carbonyl)galanthamine hydrochloride, m.p. 220-222°C.



ANALYSIS:			
Calculated for $C_{23}H_{32}N_2O_4 \cdot HCl$	63.22%C	7.61%H	6.41%N
Found	63.23%C	7.72%H	6.37%N

## EXAMPLE 6

3-O-Acetyl-6-O-demethyl-6-O-(methylaminocarbonyl)galanthamine hydrate hydrochloride

[0039] To a suspension of 6-O-demethyl-6-O-(methylaminocarbonyl)galanthamine (0.4 g) in 25 ml of dichloromethane, was added 4-dimethylaminopyridine (0.3 g) and the mixture cooled to 0 ° C. To this, was added acetic anhydride (0.2 ml) and the mixture stirred at 0 ° C for one hour; then at ambient temperature for two hours.

[0040] The solution was eluted on a silica gel column with 10% methanol/dichloromethane, and the desired fractions combined, then evaporated to a white solid, 0.33 g, m.p. 72°C. This material was dissolved in methanol, the pH adjusted to 1 with ethereal-HCl, then diluted with ether. The resultant white precipitate was collected and dried to give 0.31 g, m.p. 178°C (dec.).

ANALYSIS:			
Calculated for $C_{20}H_{24}N_2O_5 \cdot HCl \cdot 2H_2O$	53.99%C	6.57%H	6.30%N
Found	54.13%C	6.60%H	6.20%N

## EXAMPLE 7

6-O-Demethyl-6-O-(n-octylaminocarbonyl)galanthamine hydrochloride

[0041] To a mixture of 0.791 g of 6-O-demethylgalanthamine and 0.815 g of milled potassium carbonate was added 13.5 ml of THF via a syringe. The suspension was cooled to 0°C and 0.65 ml of n-octyl isocyanate was added by syringe. The suspension was filtered onto a flash chromatography column, packed with silica gel, and eluted with 3% dry methanol/dichloromethane followed by 5% dry methanol/dichloromethane to provide 1.06 g of a white solid which was dissolved in diethyl ether, and the hydrochloride salt was precipitated by addition of ethereal hydrogen chloride to provide 0.91 g of a white solid. Trituration/recrystallization from isopropyl alcohol yielded material of m.p. 210°-212°C.

ANALYSIS:			
Calculated for $C_{25}H_{36}N_2O_4 \cdot HCl$	64.57%C	8.02%H	6.02%N
Found	64.54%C	7.96%H	5.88%N

## EXAMPLE 8

6-O-Demethyl-3-O,6-O-bis(n-heptylaminocarbonyl)galanthamine hydrochloride

[0042] To a suspension of 0.8 g of 6-O-demethylgalanthamine in 14 ml of dry THF was added 1.7 ml of n-heptylisocyanate. The mixture was stirred at 72°C in a sealed tube for 72 hours and the solution concentrated to an oil. The oil was dissolved in 5% methanol/chloroform and flash chromatographed on silica gel, eluting with the same solvent system. Approximately one half of the primary product was contained in one fraction which was contaminated by a small amount (2-5%) of the lower eluting monocarbamate. This fraction was concentrated to an oil and again flash chromatographed on silica gel, eluting with 5% methanol/chloroform. The pure product-containing fractions were combined and concentrated to an oil which was dissolved in ether and the hydrochloride salt precipitated by addition of ethereal HCl. The material was dried for 2 hours at 80° to provide 0.32 g of 6-O-demethyl-3-O,6-O-bis(n-heptylaminocarbonyl)galanthamine hydrochloride, m.p. 215-217.

ANALYSIS:			
Calculated for $C_{32}H_{49}N_3O_5 \cdot HCl$	64.90%C	8.51%H	7.10%N
Found	64.64%C	8.59%H	6.98%N

## EXAMPLE 9

6-O-Demethyl-6-O-(t-butylaminocarbonyl)galanthamine hydrochloride

**[0043]** To a mixture of 1.01 g of 6-O-demethylgalanthamine and 1.03 g of milled potassium carbonate was added 16.9 ml of THF via a syringe. The suspension was cooled to 0°C and 0.52 ml of t-butyl isocyanate was added by syringe. The suspension was stirred for 1/2 hour at 0°C to 5°C and at room temperature overnight. The suspension was dissolved in methanol and filtered onto a flash chromatography column, packed with silica gel, after which it was eluted with 3% dry methanol:chloroform followed by 5% dry methanol:chloroform. The product-containing fractions were combined and concentrated to provide 0.81 g of a white, amorphous solid. The solid was dissolved in chloroform, diluted with ethyl ether, and the hydrochloride salt was precipitated by addition of ethereal hydrogen chloride to provide 0.62 g of 6-O-demethyl-6-O-(t-butylaminocarbonyl)galanthamine hydrochloride. Trituration/recrystallization using ethanol provided yielded the desired product, m.p. 230-232°C.

ANALYSIS:			
Calculated for $C_{21}H_{28}N_2O_4 \cdot HCl$	61.68%C	7.15%H	6.85%N
Found	61.46%C	7.36%H	6.68%N

## EXAMPLE 10

6-O-Demethyl-6-O-(phenylmethylaminocarbonyl)galanthamine monohydrate hydrochloride

**[0044]** To a mixture of 0.80 g of 6-O-demethylgalanthamine and 0.82 g of milled potassium carbonate was added 13.5 ml of dry THF. The suspension was cooled to 0°C after which was added 0.45 ml of benzyl isocyanate. The suspension was stirred at 0°C for 1/2 hour and filtered onto a flash chromatography column, packed with silica gel, eluted with 3% dry methyl alcohol:chloroform followed by 5% dry methyl alcohol:chloroform. The product-containing fractions were combined and concentrated to provide 0.96 g of a white, amorphous solid. The solid was dissolved in chloroform, diluted with ethyl ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride to provide 0.78 g of 6-O-demethyl-6-O-(phenylmethylaminocarbonyl)galanthamine monohydrate hydrochloride. Trituration/recrystallization using isopropyl alcohol provided 0.52 g, m.p. 210-212°C.

ANALYSIS:			
Calculated for $C_{24}H_{28}N_2O_5 \cdot HCl$	62.54%C	6.34%H	6.08%N
Found	62.89%C	6.28%H	6.07%N

## EXAMPLE 11

6-O-Demethyl-6-O-(n-nonylaminocarbonyl)galanthamine hydrochloride

**[0045]** To a mixture of 0.80 g of 6-O-demethylgalanthamine and 0.81 g of milled potassium carbonate was added 13.5 ml of dry THF. The suspension was cooled to 0°C after which was added 0.69 ml of n-nonyl isocyanate. The suspension was stirred at 0°C for 1:2 hour and at room temperature for 45 minutes. The suspension was filtered onto a flash chromatography column packed with silica gel, and eluted with 3% dry methyl alcohol:chloroform followed by 5% dry methyl alcohol:chloroform. The product-containing fractions were combined and concentrated to provide 1.23 g of a yellow oil. The oil was dissolved in ethyl ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride to provide 1.07 g of 6-O-demethyl-6-O-(n-nonylaminocarbonyl)galanthamine hydrochloride. Trituration/recrystallization of the desired product using isopropyl alcohol provided 0.90 g. m.p. 205-208°C.

ANALYSIS:			
Calculated for $C_{26}H_{38}N_2O_4 \cdot HCl$	65.19%C	8.21%H	5.85%N
Found	65.26%C	8.34%H	5.73%N

## EXAMPLE 12

## 6-O-Demethyl-3-O,6-O-bis(n-butylaminocarbonyl)galanthamine hydrochloride

**[0046]** To a stirred suspension of 1.0 g of 6-O-demethylgalanthamine, and 17.5 ml of dry THF was added 1.5 ml of n-butyl isocyanate. The mixture in a sealed tube was stirred at 67° for 72 hours. The solution was concentrated to an oil and flash chromatographed on silica gel, eluting with 5% methanol/chloroform. The pure product-containing fractions were combined and concentrated to provide a quantitative yield of the bis carbamate as a yellow oil. The hydrochloride salt was precipitated by addition of ethereal hydrogen chloride and the salt isolated by filtration to provide a white solid which was dried for 2 hours at 80°. The yield of 6-O-demethyl-3-O,6-O-bis(n-butylaminocarbonyl)galanthamine hydrochloride was 0.692 g, m.p. 208-210°C.

ANALYSIS:			
Calculated for $C_{26}H_{37}N_3O_5 \cdot HCl$	61.47%C	7.54%H	8.27%N
Found	61.15%C	7.75%H	8.19%N

## EXAMPLE 13

## 6-O-Demethyl-6-O-(methylaminocarbonyl)-3-O-(propan-2-yl-carbonyl)galanthamine hydrochloride

**[0047]** To a cold suspension of 6-O-demethyl-6-O-(methylaminocarbonyl)galanthamine (EXAMPLE 2) (2.3 g) in 120 ml of dichloromethane, was added 4-dimethylaminopyridine (1.4 g) followed by a solution of isobutyric anhydride (1.5 ml) in 10 ml of dichloromethane. After stirring at ambient temperature for seven hours, the mixture was added directly to a silica gel column and eluted with 5% methanol/dichloromethane via HPLC. The desired fractions were combined and evaporated to a thick yellow oil, (2.0 g) which was dissolved in ether and adjusted to pH 1 with ethereal-HCl. The resultant white precipitate was collected and dried to give 1.7 g 135°C (dec.)

ANALYSIS:			
Calculated for $C_{22}H_{28}N_2O_5 \cdot HCl$	60.47%C	6.69%H	6.41%N
Found	59.95%C	6.27%H	6.26%N

## EXAMPLE 14

## 6-O-Demethyl-6-O-(n-octylaminocarbonyl)-3-O-(propan-2-yl-carbonyl)galanthamine hydrochloride

**[0048]** To a stirred suspension of 0.82 g of 6-O-demethyl-6-O-(n-octylaminocarbonyl)galanthamine (EXAMPLE 9) in 20.5 ml of dichloromethane was added 0.42 g of DMAP, dissolved in 1 ml of dichloromethane. The suspension was cooled to 0°C after which 0.41 ml of isobutyric anhydride was added. After a few minutes at 0°C, the reaction mixture was allowed to proceed at room temperature overnight. The mixture was then filtered onto a flash chromatography column, packed with silica gel and 3% dry methanol:chloroform, and eluted with the same solvent system followed by 5% dry methanol:chloroform. The product-containing fractions were combined and concentrated to provide 1.09 g of an oil. Precipitation of the hydrochloride salt using ethereal hydrogen chloride provided 0.65 g of 6-O-demethyl-6-O-(n-octylamino-carbonyl)-3-O-(propan-2-yl-carbonyl)galanthamine hydrochloride, m.p. 137-140°C.

ANALYSIS:			
Calculated for $C_{29}H_{42}N_2O_5 \cdot HCl$	65.09%C	8.10%H	5.23%N
Found	65.15%C	8.27%H	5.08%N

## EXAMPLE 15

## 6-O-Demethyl-6-O-(n-octylaminocarbonyl)-3-O-(t-butylcarbonyl) galanthamine monohydrate hydrochloride

**[0049]** To 0.95 g of 6-O-demethyl-6-O-(n-octylaminocarbonyl)galanthamine (EXAMPLE 9) was added 10 ml of dichloromethane via a syringe. The solution was stirred for a few minutes at room temperature after which was added 0.40 ml of triethylamine followed by 0.29 ml of trimethylacetyl chloride and 0.06 g of DMAP dissolved in 2 ml of dichloromethane.

ane. After stirring at room temperature for 4 1/2 hours, the suspension was filtered onto a flash chromatography column, packed with silica gel and 3% methyl alcohol:chloroform and eluted with the same solvent followed by 5% methyl alcohol:chloroform. The product-containing fractions were combined and concentrated to provide 1.12 g of a yellow oil. The oil was dissolved in diethyl ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride to provide 0.93 g of 6-O-demethyl-6-O-(n-octylaminocarbonyl)-3-(trimethylacetylcarbonyl)galanthamine monohydrate hydrochloride, m.p. 138-140°C.

ANALYSIS:			
Calculated for $C_{30}H_{46}N_2O_6 \cdot HCl$	63.53%C	8.35%H	4.94%N
Found	63.66%C	8.00%H	5.35%N

## EXAMPLE 16

## 7-Bromo-6-O-demethylgalanthamine

[0050] To a stirred solution of 1.38 ml (0.966 g) of t-butylamine in 36 ml of azeotropically dried toluene at -20 to -30 ° C was added dropwise 0.34 ml (1.05 g) of bromine such that the temperature remained between -20 to -30 ° C. The solution was then cooled to -70 to -75°C and a solution of 3.0 g of 6-O-demethylgalanthamine in 15 ml of DMF was added slowly by syringe such that the temperature did not rise above -70°C. The solution was stirred for 2 hours at -70 to -78°C and subsequently allowed to warm slowly to room temperature over 6 hours. The solution was again cooled to 0°C, poured into ice/ $NaHCO_3$ /water, and extracted with chloroform. The aqueous fraction was saturated with NaCl and extracted 3 times with chloroform. The chloroform extracts were dried ( $Na_2SO_4$ ), filtered and concentrated to an oil which was purified by HPLC, employing a Waters Prep 500 Instrument, and eluting with 3% methanol/chloroform, followed by 5% methanol/chloroform. The pure product-containing fractions were combined and concentrated to provide 1.83 g (47.3% based on 6-O-demethylgalanthamine, 78.9% based on bromine, the limiting reagent). Crystallization from acetone provided analytically pure 7-bromo-6-O-demethylgalanthamine. m.p. 138-141°C.

ANALYSIS:			
Calculated for $C_{16}H_{18}BrNO_3$	54.56%C	5.15%H	3.58%N
Found	54.62%C	5.50%H	3.61%N

## EXAMPLE 17

## 6-O-Demethyl-6-O-(n-pentadecylaminocarbonyl)galanthamine hydrochloride

[0051] To a stirred suspension of 0.80 g of 6-O-demethylgalanthamine in 10 ml of dry dichloromethane was added 0.50 g of carbonyldiimidazole. The mixture was stirred at room temperature for 1 hour and cooled in an ice bath after which was added 0.57 ml of acetic acid and 0.79 g of pentadecylamine. The reaction mixture was stirred at room temperature for 4.5 hours, poured into a cold saturated solution of  $NaHCO_3$ , and extracted with chloroform. The organic layer was washed with water, dried over  $Na_2SO_4$ , filtered, and concentrated to a yellow oil. The oil was dissolved in chloroform and pipetted onto a flash chromatography column packed with silica gel and 3% methanol:chloroform. The column was eluted with the same solvent system followed by 5% methanol:chloroform. The pure, product-containing fractions were combined and concentrated to a yellow oil weighing 0.72 g. The oil was dissolved in diethyl ether and the hydrochloride salt precipitated by addition of ethereal hydrogen chloride to provide 6-O-demethyl-6-O-(n-pentadecylaminocarbonyl)galanthamine hydrochloride, m.p. 188-191 ° C d.

ANALYSIS:			
Calculated for $C_{32}H_{50}N_2O_4 \cdot HCl$	68.24%C	9.13%H	4.97%N
Found	67.91%C	9.08%H	5.08%N

## EXAMPLE 18

## 6-O-Demethyl-6-O-(dimethylaminocarbonyl)galanthamine hydrochloride

[0052] To a stirred suspension of 0.81 g of 6-O-demethylgalanthamine, 8.1 ml of dry chloroform, and 0.29 ml of


dimethylcarbamyl chloride was added 0.44 ml of 1,8-diazabicyclo[5.4.0]-undec-7-ene. The mixture was allowed to stir at room temperature overnight after which it was filtered onto a flash chromatography column, packed with silica gel and 3% methanol:chloroform and eluted with the same solvent system, followed by 5% methanol:chloroform. The pure, product containing fractions were combined and concentrated to provide 0.56 g of an off-white solid. Recrystallization of the solid using cyclohexane:ether, followed by precipitation of the hydrochloride salt using ethereal hydrogen chloride provided 6-O-demethyl-6-O-(dimethylaminocarbonyl)-galanthamine hydrochloride, m.p. 270-272°Cd.

ANALYSIS:			
Calculated for $C_{19}H_{24}N_2O_4 \cdot HCl$	59.92%C	6.62%H	7.36%N
Found	59.72%C	6.61%H	7.23%N

[0053] It should be understood that this specification and examples are set forth by way of illustration and not limitation and that various modifications and changes may be made without departing from the spirit and scope of the present invention as defined by the appended claims.

### Claims

1. A compound of the formula (II)



(II)

wherein

R<sup>1</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl, mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl, or di(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl;  
 R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy, di(C<sub>1</sub>-C<sub>3</sub>)alkylaminocarbonyloxy, or aryl(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyloxy;  
 R<sup>3</sup> is hydrogen, halo or (C<sub>1</sub>-C<sub>4</sub>)alkyl; or a pharmaceutically acceptable acid addition salt thereof.

2. A compound of claim 1, wherein

R<sup>1</sup> is mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl or (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl;  
 R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy or phenyl(C<sub>1</sub>-C<sub>3</sub>)alkylaminocarbonyloxy; and  
 R<sup>3</sup> is hydrogen or halogen; or a pharmaceutically acceptable acid addition salt thereof.

3. A compound of claim 2, wherein


R<sup>1</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl or (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl;  
 R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>10</sub>)alkylaminocarbonyloxy, or phenyl(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy;  
 R<sup>3</sup> is hydrogen; or a pharmaceutically acceptable acid addition salt thereof.

4. A compound of claim 3, wherein

R<sup>1</sup> is methylcarbonyl, ethylcarbonyl, isopropylcarbonyl, t-butylcarbonyl, n-heptylcarbonyl or t-butoxycarbonyl;  
 R<sup>2</sup> is methylaminocarbonyloxy, isopropylaminocarbonyloxy, t-butylaminocarbonyloxy, n-pentylaminocarbonyloxy, n-hexylaminocarbonyloxy, n-heptylaminocarbonyloxy, n-octylaminocarbonyloxy or n-nonylaminocarbonyloxy; and  
 R<sup>3</sup> is hydrogen; or a pharmaceutically acceptable acid addition salt thereof.

**EP 1 020 469 A2**

5. The compound as defined in claim 1, which is 6-O-demethyl-6-O-methylaminocarbonyl-3-O-(2-propylcarbonyl) galanthamine or a pharmaceutically acceptable acid addition salt thereof.
6. A pharmaceutical composition which comprises a compound of the formula II as defined in any one of claims 1-5 and a pharmaceutically acceptable carrier therefor.
7. Use of a compound of the formula II as defined in any of claims 1 to 5, for the preparation of a medicament being useful for the treatment of memory dysfunction characterized by decreased cholinergic function.



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 020 469 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
26.07.2000 Bulletin 2000/30

(51) Int Cl.7: **C07D 491/06, A61K 31/55**  
// (C07D491/06, 307:00, 223:00)

(43) Date of publication A2:  
19.07.2000 Bulletin 2000/29

(21) Application number: **00107569.6**

(22) Date of filing: **10.10.1994**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE**

(30) Priority: **15.10.1993 US 137443**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**94115960.0 / 0 648 771**

(71) Applicant: **SYNAPTECH, INC.**  
**Cold Spring Harbor, NY 11724 (US)**

(72) Inventors:


- **Kosley, JR., Raymond W.**  
**Bridgewater NJ 08807 (US)**
- **Taberna, Veronica**  
**Union NJ 07083 (US)**
- **Davis, Larry**  
**Sergeantsville NJ 08557 (US)**

(74) Representative:

**Ebner von Eschenbach, Jennifer**  
**c/o Ladas & Parry,**  
**Dachauerstrasse 37**  
**80335 München (DE)**

(54) **Galanthamine derivatives, a process for their preparation and their use as medicaments**

(57) A compound of the formula (II)



(III)

wherein

R<sup>1</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxycarbonyl, mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl, or di(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyl;

R<sup>2</sup> is mono(C<sub>1</sub>-C<sub>12</sub>)alkylaminocarbonyloxy, di(C<sub>1</sub>-C<sub>8</sub>)alkylaminocarbonyloxy, or aryl(C<sub>1</sub>-C<sub>4</sub>)alkylaminocarbonyloxy;

R<sup>3</sup> is hydrogen, halo or (C<sub>1</sub>-C<sub>4</sub>)alkyl; or a pharmaceutically acceptable acid addition salt thereof.

EP 1 020 469 A3



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 10 7569

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 88 08708 A (DAVIS BONNIE) 17 November 1988 (1988-11-17) * page 16, 4th formula with R=COMe2 *	1,6,7	C07D491/06 A61K31/55 /(C07D491/06, 307:00,223:00)
A	EP 0 236 684 A (DAVIS BONNIE) 16 September 1987 (1987-09-16) * column 2, line 24 - line 27 *	1,6,7	
A	WO 92 20327 A (SNORRASON ERNIR) 26 November 1992 (1992-11-26) * page 43; claim 20 *	1,6,7	
A	EP 0 535 645 A (HOECHST-ROUSSEL PHARM. INC.) 7 April 1993 (1993-04-07) * compounds IIIa,Va,VIIa *	1,6,7	
A	THE MERCK INDEX 10TH EDITION: , MERCK & CO., INC. , 1983 RAHWAY, N.J., U.S.A. XP002138400 * No. 4210, page 620 *	1,6,7	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07D A61K
Place of search		Date of completion of the search	Examiner
BERLIN		23 May 2000	Frelon, D
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1502 03/82 (P04C01)



**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 7569

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8808708 A	17-11-1988	CA 1338326 A	14-05-1996
		AU 632458 B	07-01-1993
		AU 1808488 A	06-12-1988
		CA 1326632 A	01-02-1994
		JP 2503794 T	08-11-1990
		JP 2755403 B	20-05-1998
		DK 549189 A	03-01-1990
		EP 0363415 A	18-04-1990
		FI 102756 B	15-02-1999
EP 0236684 A	16-09-1987	US 4663318 A	05-05-1987
		AT 76294 T	15-06-1992
		AU 593051 B	01-02-1990
		AU 6760987 A	16-07-1987
		DE 3779149 A	25-06-1992
		GR 88300077 T	21-10-1988
		GR 3005447 T	24-05-1993
		JP 2093173 C	18-09-1996
		JP 8000778 B	10-01-1996
		JP 62215527 A	22-09-1987
WO 9220327 A	26-11-1992	AT 183084 T	15-08-1999
		AU 1873692 A	30-12-1992
		AU 658424 B	13-04-1995
		AU 1886392 A	30-12-1992
		CA 2108880 A	15-11-1992
		DE 69229781 D	16-09-1999
		DE 69229781 T	05-01-2000
		EP 0515301 A	25-11-1992
		EP 0584185 A	02-03-1994
		ES 2134215 T	01-10-1999
		GR 3031559 T	31-01-2000
		JP 6507617 T	01-09-1994
		NO 934104 A	12-11-1993
		NZ 242744 A	24-02-1997
		US 5312817 A	17-05-1994
		AT 178791 T	15-04-1999
		AU 663086 B	28-09-1995
		CA 2062094 A	15-11-1992
		CA 2103022 A	15-11-1992
		DE 69228928 D	20-05-1999
		DE 69228928 T	28-10-1999
		WO 9220328 A	26-11-1992
		EP 0515302 A	25-11-1992
		EP 0584285 A	02-03-1994
		EP 0879596 A	25-11-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 7569

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220327 A		ES 2129450 T	16-06-1999
		GR 3030046 T	30-07-1999
		JP 6507621 T	01-09-1994
		NO 934103 A	12-11-1993
		NO 983939 A	12-11-1993
		NZ 242743 A	24-02-1997
		US 5589475 A	31-12-1996
		US 5633238 A	27-05-1997
		US 5336675 A	09-08-1994
		ZA 9203505 A	24-02-1993
		ZA 9203506 A	24-02-1993
EP 0535645 A	07-04-1993	US 5153193 A	06-10-1992
		AU 649882 B	02-06-1994
		AU 2606592 A	08-04-1993
		CA 2079548 A	02-04-1993
		CZ 281982 B	16-04-1997
		FI 924370 A	02-04-1993
		FI 953443 A	14-07-1995
		FI 981710 A	06-08-1998
		HU 65277 A,B	02-05-1994
		IL 103304 A	05-12-1996
		JP 2703157 B	26-01-1998
		JP 5194519 A	03-08-1993
		MX 9205577 A	01-04-1993
		NO 301884 B	22-12-1997
		NZ 244540 A	27-04-1995
		US 5234941 A	10-08-1993
		US 5231093 A	27-07-1993

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82